Impact of Mental Disorders on the Association Between Adherence to Antihypertensive Agents and All-Cause Healthcare Costs

Journal of Clinical Hypertension

Volumn 19, Issue 1, 2017, Pages 75-81

  Gentil, Lia ^a   Vasiliadis, Helen Maria ^a,b   Préville, Michel ^a,b   Berbiche, Djamal ^b  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b HÔPITAL CHARLES LEMOYNE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NITRIC ACID DERIVATIVE; NITRITE; VASODILATOR AGENT;

AGED; ANXIETY; ARTICLE; CONTROLLED STUDY; DEPRESSION; EMERGENCY CARE; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL FEE; MEDICATION COMPLIANCE; OUTPATIENT CARE; PATIENT COMPLIANCE; POPULATION RESEARCH; PRIORITY JOURNAL; ANXIETY DISORDER; COMPLICATION; ECONOMICS; HOSPITAL EMERGENCY SERVICE; PSYCHOLOGY; QUESTIONNAIRE; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; ANXIETY DISORDERS; DEPRESSION; EMERGENCY SERVICE, HOSPITAL; FEMALE; HEALTH CARE COSTS; HUMANS; HYPERTENSION; MALE; MEDICATION ADHERENCE; SURVEYS AND QUESTIONNAIRES;

EID: 84994112914     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.12869     Document Type: Article

References (33)

1. Public Health Agency of Canada. Report from the Canadian Chronic Disease Surveillance System: Hypertension in Canada, 2010. Ottawa, ON: Public Health Agency of Canada [online]; 2010. http://www.phac-aspc.gc.ca/cd-mc/cvd-mcv/ccdss-snsmc-2010/pdf/. Accessed July 8, 2010.
2. Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents, developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Coll Cardiol. 2011;57:2037–2114.
3. Statistics Canada. The 10 leading causes of death, 2011. Health Fact Sheets. http://www.statcan.gc.ca/pub/82-625-x/2014001/article/11896-eng.htm. Accessed April 10, 2015. Updated 2014.
4. World Health Organization. Adherence to Long-Term Therapies: Evidence for Action. Geneva, Switzerland: World Health Organization; 2003. www.who.int/chronic-conditions/en/adherence-report.pdf. Accessed December 14, 2014.
5. Esposti LD, Saragoni S, Batacchi P, et al. Antihypertensive therapy among newly treated patients: an analysis of adherence and cost of treatment over years. Clinicoecon Outcomes Res. 2010;2:113–120.
6. Monane M, Bohn RL, Gurwitz JH, et al. Compliance with antihypertensive therapy among elderly Medicaid enrollees: the roles of age, gender, and race. Am J Public Health. 1996;86:1805–1808.
7. Morris AB, Li J, Kroenke K, et al. Factors associated with drug adherence and blood pressure control in patients with hypertension. Pharmacotherapy. 2006;26:483–492.
8. Li Z, Li Y, Chen L, et al. Prevalence of depression in patients with hypertension: a systematic review and meta-analysis. Medicine (Baltimore). 2015;94:1317.
9. Player MS, Peterson LE. Anxiety disorders, hypertension, and cardiovascular risk: a review. Int J Psychiatry Med. 2011;41:365–377.
10. Gentil L, Vasiliadis HM, Préville M, et al. Association between depressive and anxiety disorders and adherence to antihypertensive medication in community-living elderly adults. J Am Geriatr Soc. 2012;60:2297–2301.
11. Dragomir A, Côté R, Roy L, et al. Impact of adherence to antihypertensive agents on clinical outcomes and hospitalization costs. Med Care. 2010;48:418–425.
12. Pesa JA, Van Den Bos J, Gray T, et al. An evaluation of the impact of patient cost sharing for antihypertensive medications on adherence, medication and health care utilization, and expenditures. Patient Prefer Adherence. 2012;6:63–72.
13. Kafonek S, Ettinger WH, Roca R, et al. Instruments for screening for depression and dementia in a long-term care facility. J Am Geriatr Soc. 1989;37:29–34.
14. Crum RM, Anthony JC, Bassett SS, Folstein MF. Population-based norms for the Mini-Mental State Examination by age and educational level. JAMA. 1993;269:2386–2391.
15. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state.” A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–198.
16. Karve S, Cleves MA, Helm M, et al. An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients. Med Care. 2008;46:1125–1133.
17. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50:105–116.
18. Karve S, Cleves MA, Helm M, et al. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin. 2009;25:2303–2310.
19. Wittchen HU, Robins LN, Cottler LB, et al. Cross-cultural feasibility, reliability and sources of variance of the Composite International Diagnostic Interview (CIDI). The Multicentre WHO/ADAMHA Field Trials. Br J Psychiatry. 1991;159:658.
20. Erdman HP, Klein MH, Greist JH, et al. A comparison of two computer-administered versions of the NIMH diagnostic interview schedule. J Psychiatr Res. 1992;26:85–95.
21. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994.
22. Bucholz KK, Marion SL, Shayka JJ, et al. A short computer interview for obtaining psychiatric diagnoses. Psychiatr Serv. 1996;47:293–297.
23. Préville M, Boyer R, Grenier S, et al. The epidemiology of psychiatric disorders in Quebec's older adult population. Can J Psychiatry. 2008;53:822–832.
24. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383.
25. Drummond MF. Methods for the Economic Evaluation of Health Care Programmes, 3rd edn. Toronto, ON: Oxford University Press; 2005.
26. Vasiliadis HM, Dionne PA, Preville M, et al. The excess healthcare costs associated with depression and anxiety in elderly living in the community. Am J Geriatr Psychiatry. 2013;21:536–548.
27. Cox BG, Cohen SB. Methodological Issues for Health Care Surveys. Statistics, Textbooks and Monographs. New York, NY: M. Dekker; 1985.
28. Trudel G, Courtemanche R, Tarte F. Validation, Coding, Entry and Weighting of Data for the Québec Health Survey, Technical Manual 87-07, Québec, Canada: Ministère de la Santé et des Services sociaux. Gouvernement du Québec [Quebec Ministry of Health and Social Services]; 1992.
29. McCullagh P, Nelder J. Generalized Linear Models. New York, NY: Chapman & Hall; 1983.
30. Cummings KM, Kirscht JP, Binder LR, Godley AJ. Determinants of drug treatment maintenance among hypertensive persons in inner city Detroit. Public Health Rep. 1982;97:99–106.
31. Gentil L, Vasiliadis HM, Préville M, Berbiche D. Adherence to oral antihyperglycemic agents among older adults with mental disorders and its effect on health care costs, Quebec, Canada, 2005-2008. Prev Chronic Dis. 2015;12:E231.
32. Strik JJ, Denollet J, Lousberg R, Honig A. Comparing symptoms of depression and anxiety as predictors of cardiac events and increased health care consumption after myocardial infarction. J Am Coll Cardiol. 2003;42:1801–1807.
33. Simon JD, Peter RJ, John P, David JN. Treatment of anxiety and depressive disorders in patients with cardiovascular disease. BMJ. 2004;328:939–943.